Icatibant Fresenius (Icatibant Acetate)

Icatibant is a competitive antagonist of the bradykinin B2 receptor on vascular endothelial cells. By occupying this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are key steps in the formation of edema during hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and additional doses may be given if needed, following the prescriber’s instructions.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Icatibant Fresenius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and any necessary import documentation.

The primary alternative to icatibant is plasma‑derived or recombinant C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant directly blocks the bradykinin B2 receptor, offering a rapid, self‑administered subcutaneous option, whereas C1‑inhibitor products are given intravenously and act upstream in the cascade.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, as recommended by the manufacturer.

Icatibant is administered by subcutaneous injection, usually into the abdomen or thigh. The injection can be performed by the patient or a caregiver after appropriate training. The device is a pre‑filled syringe or autoinjector, and the site should be rotated to minimize local irritation.

Serious adverse reactions include hypersensitivity events such as rash, itching, or anaphylaxis, as well as severe abdominal pain and rare cases of thrombocytopenia. Patients should be instructed to seek immediate medical attention if they experience any signs of a severe allergic reaction or unexplained, worsening abdominal discomfort.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or ARBs, as the combined effect on bradykinin may increase the risk of angioedema. Pregnant or nursing women should only use it when clearly indicated by a physician.